Background: Multiple myeloma (MM) remains incurable despite advances in available therapy. Mutations within the RAS-MAPK pathway are frequently associated with relapsed/refractory disease, with KRAS being particularly prevalent. Increased efforts to target this pathway with the MEK inhibitor, trametinib (Tr) have been limited by toxicities and the development of resistance due to adaptive signalling networks. Dexamethasone (Dex) is a corticosteroid commonly used in clinical practice, to synergistically enhance efficacy of anti-myeloma therapy. Therefore, we hypothesised that the combination of Tr and Dex would yield synergistic activity in KRAS-mutant MM. Methods: Sensitivity to Tr and Dex was determined via CellTiter-Blue (CTB) assay in the KRAS-mutant multiple myeloma cell lines (MMCLs): MM1R (Dex-refractory) & MM1S (Dex-sensitive). Apoptosis and cell cycle were evaluated by flow cytometry. Reverse phase protein array (RPPA) was employed for quantitative analysis of 60 proteins and validated by Western blotting. Results: CTB assay demonstrated a dose-dependent reduction in cell proliferation with Tr and Dex individually in MM1S, while MM1R was resistant to both treatments. TrDex demonstrated synergistic cytotoxicity in MM1S using CTB and annexin V staining. An accumulation of sub-G 1 cells was observed during cell cycle analysis in MM1S, confirming increased cell death. These effects were accompanied by activation of proapoptotic proteins, such as cleaved PARP and increased BIM. RPPA revealed the following phospho-proteins were downregulated with TrDex in MM1S compared to MM1R: FAK, PYK2, FLT3, NDRG1 and 4EBP1. Changes in phospho-NDRG1 were statistically significant (P < 0.001; 2-way ANOVA). This was confirmed by Western blotting, where expression levels were downregulated by TrDex in MM1S but unaffected in the resistant cell line MM1R. We tested the sensitivity of Galunisertib (LY21209761), a TGF-b R1 inhibitor, in HCT116 and LOVO cells the treatment by using MTT, softagar colony forming, cell invasion and wound healing assays. To study the correlation between these two pathways, we generated stable LOVO short hairpin RNA (shRNA)-sh-AXL cells clones, in which AXL expression was decreased, and stimulated both parental and shAXL LOVO cells with TGF-b1. Results: TGF-b receptors 1 and 2 were expressed in all cell lines, whereas AXL was expressed only in HCT116, SW480, LOVO cells. Treatment with Galunisertib had a modest effect on cancer cell growth, whereas it significantly decreased TGF-b induced cell migration, invasion and colony formation in HCT116 and LOVO cells (that coexpressed both TGF-b receptors and AXL). The stimulation of HCT116 and LOVO cells with TGF-b1 resulted in increased levels of phosphorylated (p) AXL, pAKT, and p38 MAPK proteins. However, in contrast to parental LOVO cells, no increase in p38 MAPK was found in LOVO shAXL clones, upon TGF-b stimulation. Conclusions: In HCT116 and LOVO cells, TGF-b mediated cell migration, invasion and soft agar colony growth formation were significantly inhibited by Galunisertib treatment. Furthermore, a functional potential cross talk between TGF-b induced signalling and AXL could converge on p38 MAPK activation. In this respect, combined treatments with Galunisertib and AXL inhibitors are ongoing to evaluate their antitumor effects in CRC cells.
Background: AXL and transforming growth factor b (TGF-b) are correlated with epithelial to mesenchymal transition, invasiveness, angiogenesis and immune modulation in colorectal cancer (CRC) . We have previously demonstrated that targeting AXL caused a significant blockade of cancer cell proliferation and migration. Here we have evaluated the role of TGF-b signalling and the potential interaction between TGF-b and AXL in human CRC cell lines. Methods: We assessed the expression and activation of TGF-b and AXL in a panel of human CRC cell lines (HCT116, SW480, LOVO, LIM 1215 and SW48) by Western Blot (WB) and Real time PCR. We tested the sensitivity of Galunisertib (LY21209761), a TGF-b R1 inhibitor, in HCT116 and LOVO cells the treatment by using MTT, softagar colony forming, cell invasion and wound healing assays. To study the correlation between these two pathways, we generated stable LOVO short hairpin RNA (shRNA)-sh-AXL cells clones, in which AXL expression was decreased, and stimulated both parental and shAXL LOVO cells with TGF-b1. Results: TGF-b receptors 1 and 2 were expressed in all cell lines, whereas AXL was expressed only in HCT116, SW480, LOVO cells. Treatment with Galunisertib had a modest effect on cancer cell growth, whereas it significantly decreased TGF-b induced cell migration, invasion and colony formation in HCT116 and LOVO cells (that coexpressed both TGF-b receptors and AXL). The stimulation of HCT116 and LOVO cells with TGF-b1 resulted in increased levels of phosphorylated (p) AXL, pAKT, and p38 MAPK proteins. However, in contrast to parental LOVO cells, no increase in p38 MAPK was found in LOVO shAXL clones, upon TGF-b stimulation. Conclusions: In HCT116 and LOVO cells, TGF-b mediated cell migration, invasion and soft agar colony growth formation were significantly inhibited by Galunisertib treatment. Furthermore, a functional potential cross talk between TGF-b induced signalling and AXL could converge on p38 MAPK activation. In this respect, combined treatments with Galunisertib and AXL inhibitors are ongoing to evaluate their antitumor effects in CRC cells. Background: AKT/PKB is a protein kinase that plays a key role in cancer, as different oncogenic pathways on it. Three isoforms with a similar structure have been described: AKT1/PKBa, AKT2/PKBb and AKT3/PKBc. Although there is evidence that each isoform yields specific functions, which may vary depending on the cell type, the data available about downstream pathways is scarce. Our project evaluates the consequences of the individual inhibition of each isoform in pancreatic adenocarcinoma cells. Methods: We have individually silenced each AKT isoform short hairpin RNAs (shRNAs) delivered by lentiviral transduction. Cells transduced with an unspecific shRNA were used as controls. Then, high-throughput quantitative proteomic analyses were performed to evaluate the differential signaling routes altered by silencing of each AKT isoform. Lastly, Western Blot and proliferation, apoptosis and chemosensitivity experiments have been completed. Results: 3930 proteins were identified with a false discovery rate (FDR) lower than 1%. Proteome pairwise comparisons were performed with the cells lines. The specific silencing of each isoform lead to differential protein expression profiles, although KEGG pathway analysis tools revealed that many of the pathways altered were common. Individual silencing of any AKT isoform caused an inhibition of glycolysis and a subsequent increase of mitochondrial activity, as seen by fluorescent mitochondrial staining. AKT silencing increased gemcitabine sensitivity for all isoforms. AKT1 and AKT2 increased 5-FU sensitivity, while AKT3 had a comparable value. Western Blot demonstrated an increase in mTOR expression after AKT1 and AKT2 silencing. p-EIF4B expression was decreased after AKT2 and AKT3 silencing. No differences were observed in ERK expression. Conclusions: AKT isoforms have specific functions in pancreatic adenocarcinoma. Its silencing drives cancer cells from aerobic glycolysis to mitochondrial dependent metabolism. A deeper knowledge of its downstream molecular pathways might give the rationale for individual pharmacological inhibition and combination with other therapies, thus improving the efficacy of the available treatments. Legal entity responsible for the study: Immunomodulation Group. Navarrabiomed / Fundaci on Miguel Servet. Background: Very little is known about receptor tyrosine kinases (RTK) expression on peripheral blood mononuclear cells (PBMC) in humans including renal cell carcinoma (RCC) patients. The primary objective of study was to evaluate expression levels of major RTKs on PBMC and tumor infiltrating lymphocytes (TIL) isolated from RCC patients. The secondary aim was to compare levels of RTK expression in RCC patients before surgery and on the 180th day after surgery (lymphocyte lifetime) and to compare with expression in healthy donors (HD). In addition, we compared RTK and PD-L1 expression in TIL. Methods: Tumor and blood samples were obtained from 20 patients with primary RCC immediately after surgical resection. Blood samples were collected from 10 HD. Tumors were harvested into RPMI1640 medium (Gibco) and processed within 4 h. TIL isolation was performed under modified protocol [Baldan 2015] . Isolated TIL and PBMC were prepared for flow cytometry. Cells were double stained with anti-CD45 FITC-conjugated mouse antibody and with PE-conjugated mouse antibodies to VEGFR1-2, PDGFRa-b, FGFR2 (all Sony Biotech) and were analyzed on NovoCyte 2000R flow cytometer (ACEA Biosciences). Expression of RTK was evaluated with NovoExpress Software. 20 tumors from same patients were stained with PD-L1 IHC assay (clone SP142 (Ventana). Results: PBMC/TIL express RTKs (Table) . In HD PBMC express all RTKs in 2-3 times higher than PBMC of RCC patients (all P < 0.05). TIL also had lower expression of RTK (all P < 0.05). There was no significant recovery of RTK expression on 180th day except of VEGFR2. Level of FGFR2 was lower on TIL (P ¼ 0.03). 50% of patients had PD-L1 expression (1-11% of positive TIL). We found negative correlation of PDGFRa, b and PD-L1 expression (P ¼ 0.04). Background: New technology, including next-generation sequencing, has been contributing to discover novel genes and a genetic mechanism connected to oncology. Oncogenes are of particular interest to biologists, as they can provide a direct target for small molecule inhibitors. However, recent studies show that tumor suppressors and oncogenes are separable using rates of truncating mutations, mutation clustering, and copy number data. At the same time, existing literature suggested a higher intensity of purifying selection on cancer-related genes. This has led to hypothesize those oncogenes and tumor suppressor genes are more closely related physically, than noncancerrelated genes. The aim of this study was to carry out clustering protein genes based on GO-terms and determine cluster structure and oncogene positions on it. Methods: List of protein-coding genes was obtained with biomaRt Bioconductor package. ClusterProfiler Bioconductor package was used to get gene ontology data of the genes. The association of genes to cancer was calculated with OncoScore Bioconductor package. Data associated with biological processes, cellular components, and molecular functions were presented in a binary format that was used for clustering analysis. SeqSphere software used for generating minimum spanning trees (MST).
Results: 15521 out 19295 protein-coding genes (85.5%) had full information about biological processes, cellular components, and molecular functions. Among 15521 genes (1.5%), 226 genes were high associated with cancer (75 and higher oncoscore). 1441 protein-coding genes had a medium association with cancer (50-74 oncoscore). 5694 genes were between 21 and 49 oncoscores. 7345 genes were not oncogenes (based on oncoscore). In 815 cases it was not possible to determine the oncoscore. MST created on 206 unique GO terms (10% cutoff) of 15521 genes revealed grape-like structure with many clusters. High associated gene to cancer (oncogenes with high oncoscore) was distributed across different clusters and located on the outer layer of clusters.
Conclusions: Cluster analysis of protein-coding genes based on GO-terms (on biological process, molecular functions, and cell localization data) demonstrated cluster (grape-like) structure. Oncogenes were located mostly outside the cluster center. Background: The Wnt/beta-catenin pathway is one of the main pathways that are dysregulated in several malignancies, including breast cancer, and may therefore be a potential therapeutic target. We have investigated the anticancer activity of PNU-74654 in breast cancer, as a Wnt/ b-catenin inhibitor, either alone or in combination with 5-FU in vitro and in vivo. Methods: Cell viability was assessed in 2 and 3-dimensional (D) cell culture models. The ability of PNU-74654 to inhibit the chemotaxis of cells was investigated using an in vitro migration assay, and the expression of several candidate genes involved in the cell cycle, migration, as well as the markers of Wnt/b-catenin pathway were investigated by qRT-PCR and/or Western blotting as well as cell cycle analysis by flow cytometry. The effect of PNU-74654 on oxidative balance was evaluated by determining the malondialdehyde (MDA) and concentration of total thiols (T-SH), and the activity of catalase (CAT) and superoxide dismutase (SOD). We reconstructed a Boolean network in order to understand dynamic behavior of genes, while the robustness of this model was assessed by Hamming distance. Results: PNU-74654 suppressed cell growth at an IC50 of 12260.4 umol/L and synergistically enhanced the antiproliferative activity of gemcitabine by modulating the Wnt pathway. The 3-D cell culture model showed that PNU-74654 caused tumor shrinkage. It reduced the migration of MCF-7 cells (by an 18% reduction in invasive behavior) after treatment with PNU-74654 through perturbation of E-cadherin and MMP3/9. PNU-74654/5-FU combination enhanced the percentages of cells in S-phase, and significantly increased apoptosis. Moreover, our data showed that this agent was able to inhibit the growth of tumor in a xenograft model, although this effect was more pronounced in the animals treated with PNU-74654 plus 5-FU. Background: CDK4/6 inhibitors have been widely used around the world for advanced estrogen receptor positive breast cancer patients in the past several years. However, the benefit offered by CDK4/6 inhibitors is individually different, therefore it is imperative need to identify the biomarker and/or monitoring marker.
